Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
March 29, 2007
By: Tim Wright
Riccardo Trecroce has been appointed chief executive officer of Patheon, Inc. Mr. Trecroce was initially appointed to this position on an interim basis in September 2006. “Since joining Patheon in 2000, Mr. Trecroce has played a key role in the development and execution of Patheon’s business strategy,” said Peter Green, chairman of Patheon. “Riccardo’s in-depth knowledge of the company, strong client focus and vision are qualities that will serve Patheon well as we move forward to advance Patheon’s positioning as a global leader in our sector.” Also, Patheon has entered into an agreement with J.P. Morgan Securities Inc. and GE Commercial Finance for new credit facilities to refinance its North American and UK debt. The refinancing is based on the completion of the $150 million convertible preferred share investment by JLL Partners Fund V, L.P., which is expected to close, together with the JLL Partners investment, by April 30th. The new credit facilities total $225 million, comprising a seven-year $150 million term loan facility and a five-year $75 million revolving facility. The proceeds of the term facility, together with the proceeds of the JLL Partners investment, will be used to repay the company’s obligations under its existing North American and U.K. credit facilities. “Today’s agreement with JPMorgan and GE Commercial Finance marks the next major milestone in our capital restructuring process,” said John Bell, chief financial officer, Patheon. “With the investment by JLL Partners and the new long-term debt facilities, we will have the appropriate long-term financial structure in place to operate and grow our business effectively.” “The JLL investment and bank refinancing are important to the future of Patheon and represent the culmination of an extensive strategic and financial alternatives review process undertaken over the past six months,” said Mr. Trecroce. The Toronto Stock Exchange has granted approval for the issuance of the convertible preferred shares to JLL Partners. However, the TSX requires Patheon’s common shareholders have the right to elect six of the nine members of Patheon’s board of directors, but will not be entitled to vote to elect the three directors who will be JLL Partners’ representatives under the terms of the agreement.
Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !